SCHEMBL30946236

SCHEMBL30946236

Cc1cc2cc(CNC(=O)N3CCCC3)[nH]c2cc1OCc1cscn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 4/20 0.36
▸ MET P08581 1/20 0.35
▸ SCD O00767 1/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ PDK1 Q15118 1/20 0.32
▸ GRM5 P41594 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.31
▸ PDE10A Q9Y233 1/20 0.31
▸ MAPK14 Q16539 1/20 0.31
▸ TPSAB1 Q15661 1/20 0.31
▸ TPSD1 Q9BZJ3 1/20 0.31
▸ TPSG1 Q9NRR2 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ OPRM1 P35372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27246866 1.00 MAPK1 (0.36) MAPK1METSCDSMN1; SMN2CYP1A2
SCHEMBL27247858 0.98 MAPK1 (0.36) MAPK1METSCDSMN1; SMN2CYP1A2
SCHEMBL30946072 0.98 MAPK1 (0.36) MAPK1METSCDSMN1; SMN2CYP1A2
SCHEMBL27247420 0.89 MET (0.35) MAPK1METSCDRAB9AGRM5
SCHEMBL27247117 0.89 GRM5 (0.37) MAPK1METSMN1; SMN2CYP2C9CYP2C19
SCHEMBL30946117 0.89 GRM5 (0.37) MAPK1METSMN1; SMN2CYP2C9CYP2C19
SCHEMBL30946212 0.89 MET (0.35) MAPK1METSCDRAB9AGRM5
SCHEMBL30920146 0.88 GRM5 (0.37) MAPK1METSMN1; SMN2CYP2C9CYP2C19
SCHEMBL30946218 0.88 MAPK1 (0.34) MAPK1METSCDRAB9AGRM5
SCHEMBL27247071 0.88 GRM5 (0.37) MAPK1METSMN1; SMN2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199546-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF SLC6A19, SLC2A9, SLC6A3 MAPK1 3172/4885MET 1337/4885SCD 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback